Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations

Virology

Volumn 443, Issue 2, 2013, Pages 329-337

  Duggal, Nisha K ^a,b   Fu, Wenqing ^a   Akey, Joshua M ^a   Emerman, Michael ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Alu elements; Apobec3 locus; Apobec3D; Common polymorphisms; HIV; Human evolution

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3E; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; HYDROLASE; UNCLASSIFIED DRUG;

APOBEC3 GENE; APOBEC3A GENE; APOBEC3B GENE; APOBEC3C GENE; APOBEC3D GENE; APOBEC3E GENE; APOBEC3F GENE; APOBEC3G GENE; APOBEC3H GENE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCUS; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HOST RESISTANCE; HUMAN; MOLECULAR EVOLUTION; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PURIFYING SELECTION; RETROPOSON; SINGLE NUCLEOTIDE POLYMORPHISM;

ALU ELEMENTS; APOBEC3 LOCUS; APOBEC3D; COMMON POLYMORPHISMS; HIV; HUMAN EVOLUTION;

ALU ELEMENTS; ANTIVIRAL AGENTS; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; EVOLUTION, MOLECULAR; GENE FREQUENCY; GENETICS, POPULATION; GENOME, HUMAN; HIV-1; HUMANS; POLYMORPHISM, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84880508303     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.05.016     Document Type: Article

References (56)

1. Alisch R.S., Garcia-Perez J.L., Muotri A.R., Gage F.H., Moran J.V. Unconventional translation of mammalian LINE-1 retrotransposons. Genes Dev. 2006, 20:210-224.
2. An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B., Alobwede I., Trono D., Vlahov D., Donfield S., Goedert J.J., Phair J., Buchbinder S., O'Brien S.J., Telenti A., Winkler C.A. APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 2004, 78:11070-11076.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Bennett E.A., Keller H., Mills R.E., Schmidt S., Moran J.V., Weichenrieder O., Devine S.E. Active Alu retrotransposons in the human genome. Genome Res. 2008, 18:1875-1883.
5. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 2004, 14:1392-1396.
6. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K.S., Moran J.V., Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:8780-8785.
7. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol.: CB 2006, 16:480-485.
8. Compton A.A., Emerman M. Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog. 2013, 9:e1003135.
9. Compton A.A., Hirsch V.M., Emerman M. The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe 2012, 11:91-98.
10. Dang Y., Abudu A., Son S., Harjes E., Spearman P., Matsuo H., Zheng Y.H. Identification of a single amino acid required for APOBEC3 antiretroviral cytidine deaminase activity. J. Virol. 2011, 85:5691-5695.
11. Dang Y., Wang X., Esselman W.J., Zheng Y.H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 2006, 80:10522-10533.
12. Dewannieux M., Esnault C., Heidmann T. LINE-mediated retrotransposition of marked Alu sequences. Nat. Genet. 2003, 35:41-48.
13. Doehle B.P., Schafer A., Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005, 339:281-288.
14. Duggal N.K., Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat. Rev. Immunol. 2012, 12:687-695.
15. Duggal N.K., Malik H.S., Emerman M. The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J. Virol. 2011, 85:11361-11371.
16. Esnault C., Heidmann O., Delebecque F., Dewannieux M., Ribet D., Hance A.J., Heidmann T., Schwartz O. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433:430-433.
17. Harari A., Ooms M., Mulder L.C., Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 2009, 83:295-303.
18. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809.
19. Hulme A.E., Bogerd H.P., Cullen B.R., Moran J.V. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 2007, 390:199-205.
20. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
21. Kidd J.M., Newman T.L., Tuzun E., Kaul R., Eichler E.E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007, 3:e63.
22. Koning F.A., Newman E.N., Kim E.Y., Kunstman K.J., Wolinsky S.M., Malim M.H. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 2009, 83:9474-9485.
23. Li M.M., Wu L.I., Emerman M. The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 2010, 84:88-95.
24. Librado P., Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics 2009, 25:1451-1452.
25. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 2004, 14:1385-1391.
26. Macmillan A.L., Kohli R.M., Ross S.R. APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J. Virol. 2013, 87:4808-4817.
27. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
28. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
29. Moran J.V., DeBerardinis R.J., Kazazian H.H. Exon shuffling by L1 retrotransposition. Science 1999, 283:1530-1534.
30. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Löwer J., Cichutek K., Flory E., Schumann G.G., Münk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 2006, 281:22161-22172.
31. Mulder L.C., Ooms M., Majdak S., Smedresman J., Linscheid C., Harari A., Kunz A., Simon V. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J. Virol. 2010, 84:9613-9617.
32. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol.: CB 2005, 15:166-170.
33. Niewiadomska A.M., Tian C., Tan L., Wang T., Sarkis P.T., Yu X.F. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J. Virol. 2007, 81:9577-9583.
34. OhAinle M., Kerns J.A., Li M.M., Malik H.S., Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 2008, 4:249-259.
35. OhAinle M., Kerns J.A., Malik H.S., Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 2006, 80:3853-3862.
36. Okeoma C.M., Lovsin N., Peterlin B.M., Ross S.R. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 2007, 445:927-930.
37. Reddy K., Winkler C.A., Werner L., Mlisana K., Abdool Karim S.S., Ndung'u T., Team C.A.I.S. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 2010, 24:195-204.
38. Refsland E.W., Hultquist J.F., Harris R.S. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 2012, 8:e1002800.
39. Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L., Harris R.S. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 2010, 38:4274-4284.
40. Ribet D., Dewannieux M., Heidmann T. An active murine transposon family pair: retrotransposition of "master" MusD copies and ETn trans-mobilization. Genome Res. 2004, 14:2261-2267.
41. Sawyer S.L., Emerman M., Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2:E275.
42. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
43. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9:1404-1407.
44. Stenglein M.D., Harris R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 2006, 281:16837-16841.
45. Tan L., Sarkis P.T., Wang T., Tian C., Yu X.F. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 2009, 23:279-287.
46. Tennessen J.A., Bigham A.W., O'Connor T.D., Fu W., Kenny E.E., Gravel S., McGee S., Do R., Liu X., Jun G., Kang H.M., Jordan D., Leal S.M., Gabriel S., Rieder M.J., Abecasis G., Altshuler D., Nickerson D.A., Boerwinkle E., Sunyaev S., Bustamante C.D., Bamshad M.J., Akey J.M., GO B., GO S. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012.
47. Turelli P., Mangeat B., Jost S., Vianin S., Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
48. Wang X., Abudu A., Son S., Dang Y., Venta P.J., Zheng Y.H. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 2011, 85:3142-3152.
49. Wei W., Gilbert N., Ooi S.L., Lawler J.F., Ostertag E.M., Kazazian H.H., Boeke J.D., Moran J.V. Human L1 retrotransposition: cis preference versus trans complementation. Mol. Cell. Biol. 2001, 21:1429-1439.
50. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004, 23:2451-2458.
51. Wissing S., Montano M., Garcia-Perez J.L., Moran J.V., Greene W.C. Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J. Biol. Chem. 2011, 286:36427-36437.
52. Yamashita M., Emerman M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 2004, 78:5670-5678.
53. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
54. Zhen A., Du J., Zhou X., Xiong Y., Yu X.F. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PloS One 2012, 7:e38771.
55. Zhen A., Wang T., Zhao K., Xiong Y., Yu X.F. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 2010, 84:1902-1911.
56. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:6073-6076.